Hypertriglyceridemia

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks

Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultane

Effect: improvement; 50% reduction in plasma triglycerides at 12 weeks